• About us
• Contact

Advertisement

Product › Details

clinical research

	Next higher product group	pharma services

Record changed: 2024-07-30

Advertisement

More documents for clinical research

• [1] Roivant Sciences GmbH. (9/10/24). "Press Release: Roivant Unveils New Pipeline Program Mosliciguat, a Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator". Basel, London & New York, NY....
• [2] Medigene AG. (9/5/24). "Press Release: Medigene Announces U.S. FDA Clearance of IND Application for MDG1015 for Multiple Solid Tumor Indications". Planegg....
• [3] Nxera Pharma Co., Ltd.. (9/2/24). "Press Release: Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568". Tokyo & Cambridge....
• [4] BioArctic AB. (8/22/24). "Press Release: Leqembi (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain". Stockholm....
• [5] BioNTech SE. (8/19/24). "Press Release: Lift of Partial Clinical Hold for BNT326/YL202"....
• [6] BioNTech SE. (8/16/24). "Press Release: Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age". New York, NY & Mainz....
• [7] Addex Therapeutics S.A.. (7/22/24). "Press Release: Addex’s Partner Discontinues ADX71149 Development in Epilepsy". Geneva....
• [8] Valneva S.E.. (7/1/24). "Press Release: Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, Ixchiq". Saint Herblain....
• [9] N-Power Medicine, Inc.. (7/1/24). "Press Release: N-Power Medicine Collaborates with Merck to Expand Oncologist and Patient Access to Clinical Trials". Redwood City, CA....
• [10] BioNTech SE. (6/24/24). "Press Release: BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer". Mainz & Shanghai....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.